TARSUS PHARMACEUTICALS INC (TARS)

Company Profile

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. The company is headquartered in Irvine, California and currently employs 87 full-time employees. The company went IPO on 2020-10-16. The Company’s lead product candidate, TP-03, is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites (Demodex blepharitis). The firm designs TP-03 to target and eradicate the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient of TP-03, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The company is also focused on investigating the development of product candidates to address targeted diseases with high unmet medical needs, which include TP-03 for the potential treatment of Meibomian Gland Disease (MGD), TP-04 for the potential treatment of rosacea, and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

Company Info

TARSUS PHARMACEUTICALS INC

15440 Laguna Canyon Road

Irvine CALIFORNIA 92618

P: 19494099820

CEO: Bobak Azamian

Employees: 87

Website: https://www.tarsusrx.com/